Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Sell
9
NONOF Quote, Financials, Valuation and Earnings
Last price:
$88.03
Seasonality move
:
9.09%
Day range:
$83.80 - $87.55
52-week range:
$79.15 - $149.55
Dividend yield:
1.7%
P/E ratio:
27.56x
P/S ratio:
9.65x
P/B ratio:
20.92x
Volume:
3.1K
Avg. volume:
69.4K
1-year change:
-19.54%
Market cap:
$377.7B
Revenue:
$33.7B
EPS (TTM):
$3.09
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Novo Nordisk AS has 11.94% upside to fair value with a price target of -- per share.
NONOF vs. S&P 500
-
Over the past 5 trading days, Novo Nordisk AS has underperformed the S&P 500 by -0.59% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Novo Nordisk AS does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novo Nordisk AS has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Novo Nordisk AS reported revenues of $10.5B.
Earnings Growth
-
Novo Nordisk AS has grown year-over-year earnings for 9 quarters straight. In the most recent quarter Novo Nordisk AS reported earnings per share of $0.90.
Enterprise value:
375B
EV / Invested capital:
--
Price / LTM sales:
9.65x
EV / EBIT:
21.18x
EV / Revenue:
9.53x
PEG ratio (5yr expected):
0.98x
EV / Free cash flow:
38.16x
Price / Operating cash flow:
38.66x
Enterprise value / EBITDA:
18.61x
Gross Profit (TTM):
$33.3B
Return On Assets:
28.14%
Net Income Margin (TTM):
35.03%
Return On Equity:
88.95%
Return On Invested Capital:
65.63%
Operating Margin:
47.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $24.3B | $30.8B | $39.4B | $8.6B | $10.5B | |
| Gross Profit | $20.5B | $25.9B | $33.3B | $7.2B | $8.8B | |
| Operating Income | $10.4B | $13.4B | $17.2B | $3.9B | $5B | |
| EBITDA | $11.6B | $14.1B | $20.2B | $4.8B | $5.5B | |
| Diluted EPS | $1.68 | $2.41 | $3.09 | $0.73 | $0.90 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $11.6B | $14.2B | $15.8B | $20.1B | $29.2B | |
| Total Assets | $22.1B | $27.2B | $32.1B | $42.5B | $59.5B | |
| Current Liabilities | $11.2B | $13.8B | $17.2B | $24.4B | $31.2B | |
| Total Liabilities | $12.7B | $16.8B | $22B | $29.3B | $41.5B | |
| Total Equity | $9.4B | $10.3B | $10.1B | $13.2B | $18.1B | |
| Total Debt | $647.1M | $2.1B | $3.4B | $3.8B | $8.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.3B | $16B | $17.3B | $6B | $6.7B | |
| Cash From Investing | -$4.8B | -$6.3B | -$7.7B | -$1.9B | -$3.1B | |
| Cash From Financing | -$5.3B | -$9.1B | -$5.6B | -$2.9B | -$2.7B | |
| Free Cash Flow | $7.7B | $11.8B | $9.8B | $4.4B | $4.7B | |
NONOF
Sector
Market Cap
$377.7B
$47.1M
Price % of 52-Week High
56.86%
48%
Dividend Yield
1.7%
0%
Shareholder Yield
1.69%
-0.74%
1-Year Price Total Return
-19.54%
-33.14%
Beta (5-Year)
0.510
0.754
Dividend yield:
1.7%
Annualized payout:
$1.03
Payout ratio:
46.98%
Growth streak:
3 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$85.85
200-day SMA
Sell
Level
$123.63
Bollinger Bands (100)
Sell
Level
99.35 - 129.37
Chaikin Money Flow
Buy
Level
1.8M
20-day SMA
Sell
Level
$94.98
Relative Strength Index (RSI14)
Sell
Level
32.42
ADX Line
Sell
Level
30.44
Williams %R
Buy
Level
-80.2176
50-day SMA
Sell
Level
$102.41
MACD (12, 26)
Sell
Level
-6.19
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
2.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.0357)
Buy
CA Score
(Annual)
Level (0.8259)
Buy
Beneish M-Score
(Annual)
Level (-2.5531)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-1.5637)
Buy
Piotroski F Score
(Annual)
Level (8)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Stock Forecast FAQ
In the current month, NONOF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NONOF average analyst price target in the past 3 months is --.
-
Where Will Novo Nordisk AS Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novo Nordisk AS share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Novo Nordisk AS?
Analysts are divided on their view about Novo Nordisk AS share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novo Nordisk AS is a Sell and believe this share price will drop from its current level to --.
-
What Is Novo Nordisk AS's Price Target?
The price target for Novo Nordisk AS over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NONOF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novo Nordisk AS is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NONOF?
You can purchase shares of Novo Nordisk AS via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novo Nordisk AS shares.
-
What Is The Novo Nordisk AS Share Price Today?
Novo Nordisk AS was last trading at $88.03 per share. This represents the most recent stock quote for Novo Nordisk AS. Yesterday, Novo Nordisk AS closed at $85.04 per share.
-
How To Buy Novo Nordisk AS Stock Online?
In order to purchase Novo Nordisk AS stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Why Is General Electric Stock Going Up?
General Electric Company, doing business these days as GE Aerospace…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
1
IONQ alert for Jan 10
IonQ [IONQ] is up 6.61% over the past day.
Sell
45
COLL alert for Jan 10
Collegium Pharmaceutical [COLL] is down 2.64% over the past day.
Sell
30
EDN alert for Jan 10
Empresa Distribuidora y Comercializadora Norte SA [EDN] is down 0.64% over the past day.
